JPH0686377B2 - Cancer metastasis inhibitor - Google Patents
Cancer metastasis inhibitorInfo
- Publication number
- JPH0686377B2 JPH0686377B2 JP60215211A JP21521185A JPH0686377B2 JP H0686377 B2 JPH0686377 B2 JP H0686377B2 JP 60215211 A JP60215211 A JP 60215211A JP 21521185 A JP21521185 A JP 21521185A JP H0686377 B2 JPH0686377 B2 JP H0686377B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ethyl ester
- group
- eicosapentaenoic acid
- acid ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は、ヒトのがん、特に肺へのがんの転移抑制剤に
関する。TECHNICAL FIELD The present invention relates to an agent for suppressing metastasis of human cancer, particularly lung cancer.
ヒトのがんの治療法としては、がん組織を切除する外科
的方法、放射線を用いる放射線療法、制がん剤を用いる
化学療法がある。これらの治療方法は、単独または組合
わせて実施されるが、それぞれ以下のような限界があ
る。Treatments for human cancer include surgical methods of excising cancer tissue, radiation therapy using radiation, and chemotherapy using anti-cancer drugs. These treatment methods may be used alone or in combination, but each has the following limitations.
外科的方法では、がん組織がびまん性であつたり、原発
部位から他の臓器に転移している場合には手術の不可能
なことがある。放射線療法では、がん組織だけでなく正
常組織も放射線による障害を受けるため、がん組織を根
本的に破壊するに充分な放射線を照射することができな
い場合がある。また、化学療法でも同様に、化学療法剤
によつて正常組織も障害を受けるため、体内に存在する
すべてのがん細胞を破壊するために充分な量の化学療法
剤を投与できない場合がある。Surgical methods may be inoperable if the cancerous tissue is diffuse or has spread from the primary site to other organs. In radiation therapy, not only cancer tissue but also normal tissue is damaged by the radiation, and thus it may not be possible to irradiate with sufficient radiation to fundamentally destroy cancer tissue. Similarly, in chemotherapy as well, since normal tissues are damaged by the chemotherapeutic agent, it may not be possible to administer a sufficient amount of the chemotherapeutic agent to destroy all cancer cells present in the body.
がんに対する従来の治療方法である外科的方法、放射線
療法、化学療法、およびこれらを組合せる方法では充分
な効果が得られない場合があるため、新しい療法方法が
求められている。Conventional therapeutic methods for cancer, such as surgical methods, radiation therapy, chemotherapy, and methods that combine these methods may not provide sufficient effects, so new therapeutic methods are needed.
第一は、がん細胞が発生し、増殖し、がん組織となる場
合の環境である生体の性質を変えようとする考え方であ
る。すなわち、生体な外部から侵入する微生物等の異物
に対し防禦のための機構を備えており、免疫機構がそれ
にあたる。生体内で発生するがん細胞も異物ということ
ができ、生体にとつては排除すべきものである。しか
し、生体の防禦機能が低下している場合には、発生した
がん細胞を効率よく排除することができず、がん細胞が
増殖してしまうものと考えられている。同様に、外科的
手術等でがん組織を除いても、残存するがん細胞が再び
増殖すればがんの再発となる。そこで、がんの環境であ
る生体の性質を変え、がん細胞排除機能を賦活化しよう
という生物学的応答修飾剤（Biological Response Modi
fier,BRM）が必要とされる。The first is the idea of changing the properties of the living body, which is the environment in which cancer cells develop, proliferate, and become cancer tissues. That is, it is equipped with a mechanism for protection against foreign substances such as microorganisms invading from the outside of the living body, and the immune mechanism corresponds to it. Cancer cells that occur in a living body can also be called a foreign body, and should be excluded from the living body. However, when the anti-corrosion function of the living body is reduced, it is considered that the cancer cells that have occurred cannot be efficiently eliminated and the cancer cells grow. Similarly, even if the cancer tissue is removed by a surgical operation or the like, the cancer will recur if the remaining cancer cells grow again. Therefore, the biological response modifier (Biological Response Modi
fier, BRM) is required.
第二に、がんは生体内で最初に発生する原発巣から他の
部位へしばしば転移する。とくに外科的治療の成否は、
転移の防止にかかつている。しかし、現在までのとこ
ろ、がん細胞が他の臓器へ浸出していくことを有効に抑
制する方法は存在せず、転移を抑制する効果のある薬剤
が切実に求められている。Second, cancer often spreads from the first primary tumor in the body to other sites. Especially the success or failure of surgical treatment,
I am trying to prevent metastasis. However, to date, there is no method for effectively suppressing the invasion of cancer cells into other organs, and there is an urgent need for a drug having an effect of suppressing metastasis.
本発明者らは、がん治療薬を種々検討した結果、消化器
がんの治療に有効であって、転移特に肺への転移を抑制
する効果を有する薬剤を見出した。As a result of various studies on cancer therapeutic agents, the present inventors have found a drug effective in treating digestive organ cancer and having an effect of suppressing metastasis, particularly metastasis to the lung.
よって、本発明はエイコサペタエン酸エチルエステル
（以下EPAと略記する）を含有するがん転移抑制剤に関
する。Therefore, the present invention relates to a cancer metastasis inhibitor containing eicosapetaenoic acid ethyl ester (hereinafter abbreviated as EPA).
本発明に用いるEPAは、化学名all−cis−5,8,11,14,17
−エイコサペンタエン酸またはその誘導体であり、公知
の化合物である（たとえば特開昭56−115736）。The EPA used in the present invention has a chemical name of all-cis-5,8,11,14,17.
-Eicosapentaenoic acid or its derivative, which is a known compound (for example, JP-A-56-115736).
本発明では、EPAを消化器がんの治療に有用な剤型、た
とえばカプセル剤、顆粒剤、懸濁剤、乳剤、坐剤、細粒
剤、散剤、錠剤、注射剤などとして投与し、または油脂
を吸着する性質を有する物質に吸着させて、あるいはそ
のままの形で、経口的に摂取させる。この場合の投与量
は１日当り成人に対してエイコサペンタエン酸エチルエ
ステルとして10mg〜10,000mgの範囲の量とされる。そし
て好ましい量は1,000mg〜5,000mgの範囲である。このEP
Aは１日に数回分割して投与しても良いし、また上記の
投与量を合計して２日または３日に１度づつの間隔で投
与しても良い。なお製剤中に含まれるEPAの量は0.1〜20
重量％、好ましくは約１〜10重量％であるが、とくに厳
密を要しない。In the present invention, EPA is administered in a dosage form useful for the treatment of digestive organ cancer, for example, capsules, granules, suspensions, emulsions, suppositories, fine granules, powders, tablets, injections, or the like, or It is orally ingested by adsorbing it to a substance having a property of adsorbing fats or oils, or in the form as it is. The dose in this case is in the range of 10 mg to 10,000 mg of eicosapentaenoic acid ethyl ester for an adult per day. And the preferred amount is in the range of 1,000 mg to 5,000 mg. This EP
A may be administered in several divided doses a day, or may be administered once every 2 or 3 days in total for the above doses. The amount of EPA contained in the formulation is 0.1-20
%, Preferably about 1-10%, but not critical.
本発明の治療剤は、消化器がん、たとえば大腸がんの治
療に有効である。すなわち、がんの増殖を抑制する。ま
た、外科的手術が施行された場合には、残存するがん細
胞による再発や転移を防止する。その適用に当つては、
１日１〜数回がん組織の近傍に投与するか、全身に投与
する。この場合の投与量はエイコサペンタエン酸エチル
エステルとして500mg〜10,000mgの範囲の量とされる。The therapeutic agent of the present invention is effective in treating digestive organ cancer, such as colon cancer. That is, it suppresses the growth of cancer. Also, when surgical operation is performed, recurrence or metastasis due to residual cancer cells is prevented. In applying it,
It is administered once or several times a day near the cancer tissue or systemically. In this case, the dose is 500 mg to 10,000 mg as eicosapentaenoic acid ethyl ester.
エイコサペンタエン酸は、そのグリセリドの形でイワシ
油等の魚油中に存在するものであるから、毒性を示さな
いことは自明であり、またそのエチルエステルも例えば
「プロスタグランジン」第23巻，第４号，第558頁およ
び第561頁（1982年）にも60mg/kg.日のエイコサペンタ
エン酸エチルエステルを４週間投与したところ毒性は認
められなかったとあるごとく、実際上毒性を有しない。Since eicosapentaenoic acid is present in fish oil such as sardine oil in the form of its glyceride, it is obvious that it does not show toxicity, and its ethyl ester is also known as "prostaglandin" Vol. 23, Vol. No. 4, p. 558 and p. 561 (1982), when 60 mg / kg.day of eicosapentaenoic acid ethyl ester was administered for 4 weeks, no toxicity was observed as it was, and practically it was not.
次の実施例１および３は、エイコサペンタエン酸エチル
エステルのがん細胞増殖抑制および発がん抑制作用を、
また実施例４および５は製剤化例を参考のために示した
ものであり、実施例２がエイコサペンタンエン酸エチル
エステルががん転移抑制作用を有することを示した本発
明の実施例である。The following Examples 1 and 3 show the effects of eicosapentaenoic acid ethyl ester on the suppression of cancer cell growth and carcinogenesis.
In addition, Examples 4 and 5 are shown as examples of formulation, and Example 2 is an example of the present invention showing that ethyl ester of eicosapentaenoic acid has a cancer metastasis suppressing action. is there.
次に本発明による制がん剤の作用を裏付ける実施例と製
剤化のための実施例とを示す。Next, examples showing the action of the anticancer agent according to the present invention and examples for formulation will be shown.
実施例１ がん細胞の増殖抑制 10週令のC57BL/6系の雄性マウスを１群10匹から成る２
群に分け、半合成無脂肪食（オリエンタル酵母社製）で
飼育する。１群（EPA群）は、エイコサペンタエン酸エ
チルエステルを重量で５％食餌に加えそれを１匹につき
１日当り3gの量で２週間投与する。他の１群は、対照群
とし、薬理活性がないとされているステアリン酸を重量
で５％食餌に加え、同様に投与する。ルイス肺がん細胞
を１×105個、左後肢の足蹠に移植し、各群へそれぞれ
エイコサペンタエン酸エチルエステル、ステアリン酸の
投与を続ける。ルイス肺がん細胞の移植後４、６、８、
10、11、12、13、14日めに足蹠の厚さを測定し、がん細
胞の増殖能を検討した。図面に示すように、EPA群は対
照群に比べがん細胞の増殖が抑制された（Ｐ＜0.000
1）。Example 1 Inhibition of Cancer Cell Growth 10-week-old C57BL / 6 male mice consisted of 10 mice per group 2
Divide into groups and raise them on a semi-synthetic fat-free diet (Oriental Yeast Co., Ltd.). Group 1 (EPA group) is prepared by adding eicosapentaenoic acid ethyl ester to a 5% by weight diet and administering it at an amount of 3 g per animal per day for 2 weeks. The other group is used as a control group, and stearic acid, which is considered to have no pharmacological activity, is added to the diet by 5% by weight and the same administration is performed. 1 × 10 5 Lewis lung cancer cells are transplanted into the footpad of the left hindlimb, and eicosapentaenoic acid ethyl ester and stearic acid are continuously administered to each group. 4,6,8 after transplantation of Lewis lung cancer cells,
On the 10th, 11th, 12th, 13th, and 14th days, the thickness of the footpads was measured, and the proliferation ability of cancer cells was examined. As shown in the figure, the EPA group suppressed the growth of cancer cells as compared with the control group (P <0.000).
1).
実施例２ がん細胞の肺転移抑制実験 10週令のC57BL/6の雄性マウスを１群10匹から成る２群
に分け、通常のマウス飼育用の餌（オリエンタル酵母社
製）で１週間予備飼育する。ルイス肺がん細胞１×105
個をマウスの後肢の足蹠の皮下に移植する。移植後11日
間、通常の餌で飼育し、その後、１群は、エイコサペン
タエン酸エチルエステルを重量で５％半合成無脂肪食
（オリエンタル酵母社製）に加え、それを１匹につき１
日当り4gの量で継続して投与する（EPA群）。他の１群
は対照群とし、薬理活性がないとされているステアリン
酸を重量で５％半合成無脂肪食に加えて投与する。投与
開始後３日め、すなわち移植後14日めに、がん細胞を移
植した後肢を切断し、さらに２週間継続して投与する。
移植後４週間でマウスで屠殺し、剖検して肺移転数等を
計測する。表１に示すように、EPA群では対照群に比べ
肺移転数が少なかつた。Example 2 Cancer Cell Lung Metastasis Inhibition Experiment 10-week-old C57BL / 6 male mice were divided into two groups, each group consisting of 10 mice, and preliminarily preserved for 1 week with a normal mouse-raising diet (Oriental Yeast Co., Ltd.). Breed. Lewis lung cancer cells 1 × 10 5
Individuals are implanted subcutaneously in the footpads of the hind limbs of mice. After feeding for 11 days after transplantation, the animals were fed with normal diet, and then 1 group added eicosapentaenoic acid ethyl ester to a 5% semi-synthetic fat-free diet (manufactured by Oriental Yeast Co., Ltd.), and added 1 animal per animal.
Continue to administer 4g daily (EPA group). The other group is used as a control group, and stearic acid, which is considered to have no pharmacological activity, is added to a 5% semi-synthetic fat-free diet by weight for administration. On the 3rd day after the start of administration, that is, on the 14th day after transplantation, the hind limb to which the cancer cells have been transplanted is transected, and the administration is continued for 2 weeks.
Four weeks after the transplantation, the mice are sacrificed and autopsied to measure the number of lung transfers and the like. As shown in Table 1, the number of lung transfers in the EPA group was smaller than that in the control group.
実施例３ アゾキシメタンによる発がんの抑制 ６週令の雄性ドンリュー系ラットを１群25匹で２群用
い、エイコサペンタエン酸エチルエステル（EPA群）お
よび対照群としてステアリン酸を重量で５％になるよう
半合成無脂肪食（オリエンタル酵母社製）に加え、それ
を１匹につき１日当り30gの量で継続して投与する。発
がん剤であるアゾキシメタンは、投与開始後１週間めか
ら7.4mg/kg/週で11回皮下注射した。投与開始後31週め
に動物を屠殺し、剖検して大腸がんの発生個数を計測し
た。表２に示すように、EPA群では、対照群に比較し、
大腸がんの発生率および一匹あたりの腫瘍個数がともに
少なかつた。 Example 3 Suppression of carcinogenesis by azoxymethane Two 6-week-old male Donryu rats were used, one group consisting of 25 rats, and eicosapentaenoic acid ethyl ester (EPA group) and stearic acid as a control group at 5% by weight. In addition to a synthetic fat-free diet (Oriental Yeast Co., Ltd.), it is continuously administered in an amount of 30 g per animal per day. The carcinogen, azoxymethane, was subcutaneously injected 11 times at 7.4 mg / kg / week from the first week after the start of administration. The animals were sacrificed 31 weeks after the start of administration, and autopsy was performed to count the number of colon cancer occurrence. As shown in Table 2, in the EPA group, compared to the control group,
The incidence of colorectal cancer and the number of tumors per animal were both low.
実施例４ 軟カプセル剤 エイコサペンタエン酸エチルエステル2Kgと中鎖脂肪酸
トリグリセリド800gとを混合し、日本薬局方製剤総則に
従い、軟カプセル剤とする。１カプセルの重量は455mg
とし、内容物重量は280mg、ゼラチン皮膜であるカプセ
ル基剤は175mgとする。処方は以下の通りである。 Example 4 Soft capsule agent 2 kg of eicosapentaenoic acid ethyl ester and 800 g of medium-chain fatty acid triglyceride are mixed to obtain a soft capsule agent according to the Japanese Pharmacopoeia General Rules. The weight of one capsule is 455 mg.
The content weight is 280 mg, and the capsule base, which is a gelatin film, is 175 mg. The prescription is as follows.
内 容 物 エイコサペンタエン酸エチルエステル
200mg 中鎖脂肪酸トリグリセリド 80mg 小 計 280mg カプセル基剤 日本薬局方 ゼラチン 118.77mg 〃 濃グリセリン 18.36mg 〃 Ｄ−ソルビトール 14.69mg 〃 酸化チタン 1.59mg 〃 パラオキシ安息香酸エチル
0.24mg 〃 パラオキシ安息香酸プロピ
ル 0.12mg 〃 精製水 適量 小 計 175mg 実施例５ レクタルカプセル エイコサペンタエン酸エチルエステル2Kgと日本薬局方
カカオ脂2Kgとを混合し、ライナー社製のロータリー型
軟カプセル製造機を用い、レクタルカプセルとする。１
カプセルの重量は1,580mgとし、内容物重量は1,000mg、
ゼラチン皮膜であるカプセル基剤は580mgとする。処方
は以下の通りである。Content Eicosapentaenoic acid ethyl ester
200 mg Medium-chain fatty acid triglyceride 80 mg Subtotal 280 mg Capsule base Japanese Pharmacopoeia Gelatin 118.77 mg 〃 Concentrated glycerin 18.36 mg 〃 D-sorbitol 14.69 mg 〃 Titanium oxide 1.59 mg 〃 Ethyl paraoxybenzoate
0.24mg 〃 Propyl paraoxybenzoate 0.12mg 〃 Purified water Appropriate amount Subtotal 175mg Example 5 Rectal capsule Eicosapentaenoic acid ethyl ester 2Kg and Japanese Pharmacopoeia cacao butter 2Kg are mixed, and a rotary type soft capsule manufacturing machine manufactured by Liner is used. Used as a rectal capsule. 1
Capsule weight is 1,580 mg, content weight is 1,000 mg,
The capsule base, which is a gelatin film, is 580 mg. The prescription is as follows.
内 容 物 エイコサペンタエン酸エチルエステル
500mg 日本薬局方 カカオ脂 500mg 小 計 1,000mg ガプセル基剤 日本薬局方 ゼラチン 264mg 〃 濃グリセリン 53mg 〃 Ｄ−マンニトール 8mg 〃 精製水 適量 小 計 580mgContent Eicosapentaenoic acid ethyl ester
500 mg Japanese Pharmacopoeia Cocoa butter 500 mg Subtotal 1,000 mg Gapcel base Japanese Pharmacopoeia Gelatin 264 mg 〃 Concentrated glycerin 53 mg 〃 D-mannitol 8 mg 〃 Purified water Appropriate amount Subtotal 580 mg
図面は、ルイス肺癌細胞を１×105個マウスの足蹠に移
植した後の足蹠の厚さを測定した結果を示すグラフであ
る。The drawing is a graph showing the results of measuring the thickness of the foot pad after transplanting Lewis lung cancer cells into the foot pad of 1 × 10 5 mice.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 山本 政勝 大阪府寝屋川市菅相塚町２丁目20番地 ─────────────────────────────────────────────────── ─── Continued Front Page (72) Inventor Masakatsu Yamamoto 2-20 Sugaaitsuka-cho, Neyagawa-shi, Osaka
Claims (1)
有するがん転移抑制剤。1. A cancer metastasis inhibitor containing eicosapentaenoic acid ethyl ester.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60215211A JPH0686377B2 (en) | 1985-09-30 | 1985-09-30 | Cancer metastasis inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60215211A JPH0686377B2 (en) | 1985-09-30 | 1985-09-30 | Cancer metastasis inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6277319A JPS6277319A (en) | 1987-04-09 |
| JPH0686377B2 true JPH0686377B2 (en) | 1994-11-02 |
Family
ID=16668534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60215211A Expired - Fee Related JPH0686377B2 (en) | 1985-09-30 | 1985-09-30 | Cancer metastasis inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0686377B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2688829B2 (en) * | 1988-06-29 | 1997-12-10 | 理化学研究所 | Anticancer drug |
| EP0591303B1 (en) * | 1991-06-24 | 2000-12-06 | Women's And Children's Hospital | Methods and compositions for treating malaria and other diseases |
| NO20003591L (en) * | 2000-07-13 | 2002-01-14 | Thia Medica As | Fatty acid analogues for the treatment of cancer |
| GB0428384D0 (en) * | 2004-12-24 | 2005-02-02 | Sla Pharma Ag | Eicosapentaenoic acid |
| ES2275435B1 (en) * | 2005-11-18 | 2008-06-01 | Farmaleis, S.L. | "PHARMACEUTICAL COMPOSITION THAT INCLUDES SCALLENE AND USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER. |
| ES2704439T3 (en) * | 2007-03-20 | 2019-03-18 | Scf Pharma Inc | Compositions comprising monoglycerides of polyunsaturated fatty acids or derivatives thereof and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56115736A (en) * | 1980-02-19 | 1981-09-11 | Kagakuhin Kensa Kyokai | Separation and purification of eicosapentaenoic acid and docosahexaenoic acid |
| JPS58213716A (en) * | 1982-06-05 | 1983-12-12 | Junichi Iwamura | Carcisnostatic agent |
| JPS6058917A (en) * | 1983-09-09 | 1985-04-05 | Rikagaku Kenkyusho | Carcinostatic agent |
| JPS6183122A (en) * | 1984-08-10 | 1986-04-26 | セントラケム・リミテツド | Method of nornalizing eicosanoid balance of cell and composition therefor |
| JPH01153629A (en) * | 1987-12-11 | 1989-06-15 | Nippon Oil & Fats Co Ltd | Anticancer agent |
-
1985
- 1985-09-30 JP JP60215211A patent/JPH0686377B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56115736A (en) * | 1980-02-19 | 1981-09-11 | Kagakuhin Kensa Kyokai | Separation and purification of eicosapentaenoic acid and docosahexaenoic acid |
| JPS58213716A (en) * | 1982-06-05 | 1983-12-12 | Junichi Iwamura | Carcisnostatic agent |
| JPS6058917A (en) * | 1983-09-09 | 1985-04-05 | Rikagaku Kenkyusho | Carcinostatic agent |
| JPS6183122A (en) * | 1984-08-10 | 1986-04-26 | セントラケム・リミテツド | Method of nornalizing eicosanoid balance of cell and composition therefor |
| JPH01153629A (en) * | 1987-12-11 | 1989-06-15 | Nippon Oil & Fats Co Ltd | Anticancer agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6277319A (en) | 1987-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nigro et al. | Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil | |
| EP0201275B1 (en) | Pharmaceutical compositions for treating metastasis of cancerous tumors | |
| JP4476479B2 (en) | Drugs for the treatment or prevention of diabetic complications | |
| US4931468A (en) | Pharmaceutical and dietary composition | |
| US5385936A (en) | Gossypol acetic acid for the treatment of cancer | |
| CA2606255C (en) | Use of lecithin as a medicament for treating psoriasis | |
| MXPA01004980A (en) | Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby. | |
| EP0567653A1 (en) | Drug for hepatic diseases | |
| US6063814A (en) | Phorbol esters as anti-neoplastic and white blood cell elevating agents | |
| BR112015010703B1 (en) | use of a pharmaceutical composition and pharmaceutical composition | |
| Jacoby et al. | The effect of MGN-3 on cisplatin and doxorubicin induced toxicity in the rat | |
| JP4842436B2 (en) | Proanthocyanidin A2 phospholipid complex as anti-atherosclerotic agent | |
| KR950008767B1 (en) | Novel pharmacentical use of ebselen | |
| JPH0686377B2 (en) | Cancer metastasis inhibitor | |
| CA2535451A1 (en) | Method of treating viral infections | |
| JPS6267021A (en) | Polyunsaturated fatty acid composition and manufacture | |
| Sen | Deficient synthesis of melatonin in COVID-19 can impair the resistance of coronavirus patients to mucormycosis | |
| FR2464715A1 (en) | USE OF GLYCERYLPHOSPHORYL DERIVATIVES IN THERAPY OF DYSLIPEMIA, HEPATITIS AND SIMILAR PATHOLOGICAL CONDITIONS AND PHARMACEUTICAL COMPOSITIONS FOR THERAPY | |
| RU2485956C2 (en) | New composition for treating side effects of anti-cancer therapy | |
| US4997852A (en) | Method and composition for achieving cancer chemopreventive and chemotherapeutic activity | |
| US3432602A (en) | Oral alkyl glycerol ether improvement in radiation,radiomimetic,or cytostatic tumor therapies | |
| Gaunt et al. | Effect of reserpine (Serpasil) and hydralazine (Apresoline) on experimental steroid hypertension | |
| CN106038566B (en) | A kind of pharmaceutical composition and its application for curing gastric cancer | |
| JPH06192084A (en) | Inhibitor of cancer metastasis | |
| US5010107A (en) | Method and composition for achieving anticarcinogenic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |